Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Expressions of circadian clock genes represent disease activities of RA patients treated with biological DMARDs.

Kaneshiro K, Yoshida K, Morii K, Oketani Y, Uchida K, Yaekura A, Okumura I, Hashimoto T, Kawasaki Y, Shibanuma N, Sakai Y, Hashiramoto A.

Mod Rheumatol. 2019 May 2:1-8. doi: 10.1080/14397595.2019.1602242. [Epub ahead of print]

PMID:
30942638
2.

Methotrexate upregulates circadian transcriptional factors PAR bZIP to induce apoptosis on rheumatoid arthritis synovial fibroblasts.

Suzuki K, Yoshida K, Ueha T, Kaneshiro K, Nakai A, Hashimoto N, Uchida K, Hashimoto T, Kawasaki Y, Shibanuma N, Nakagawa N, Sakai Y, Hashiramoto A.

Arthritis Res Ther. 2018 Mar 22;20(1):55. doi: 10.1186/s13075-018-1552-9.

3.

TNF-α induces expression of the circadian clock gene Bmal1 via dual calcium-dependent pathways in rheumatoid synovial cells.

Yoshida K, Nakai A, Kaneshiro K, Hashimoto N, Suzuki K, Uchida K, Hashimoto T, Kawasaki Y, Tateishi K, Nakagawa N, Shibanuma N, Sakai Y, Hashiramoto A.

Biochem Biophys Res Commun. 2018 Jan 8;495(2):1675-1680. doi: 10.1016/j.bbrc.2017.12.015. Epub 2017 Dec 5.

4.

A variant of death-receptor 3 associated with rheumatoid arthritis interferes with apoptosis-induction of T cell.

Hashiramoto A, Konishi Y, Murayama K, Kawasaki H, Yoshida K, Tsumiyama K, Tanaka K, Mizuhara M, Shiotsuki T, Kitamura H, Komai K, Kimura T, Yagita H, Shiozawa K, Shiozawa S.

J Biol Chem. 2018 Feb 9;293(6):1933-1943. doi: 10.1074/jbc.M117.798884. Epub 2017 Nov 27.

5.

Circulating cell free DNA: a marker to predict the therapeutic response for biological DMARDs in rheumatoid arthritis.

Hashimoto T, Yoshida K, Hashimoto N, Nakai A, Kaneshiro K, Suzuki K, Kawasaki Y, Shibanuma N, Hashiramoto A.

Int J Rheum Dis. 2017 Jun;20(6):722-730. doi: 10.1111/1756-185X.12959. Epub 2016 Dec 10.

PMID:
27943573
6.

Involvement of the circadian rhythm and inflammatory cytokines in the pathogenesis of rheumatoid arthritis.

Yoshida K, Hashimoto T, Sakai Y, Hashiramoto A.

J Immunol Res. 2014;2014:282495. doi: 10.1155/2014/282495. Epub 2014 May 8. Review.

7.

IFN-γ-producing effector CD8 T lymphocytes cause immune glomerular injury by recognizing antigen presented as immune complex on target tissue.

Tsumiyama K, Hashiramoto A, Takimoto M, Tsuji-Kawahara S, Miyazawa M, Shiozawa S.

J Immunol. 2013 Jul 1;191(1):91-6. doi: 10.4049/jimmunol.1203217. Epub 2013 May 29.

8.

TNF-α modulates expression of the circadian clock gene Per2 in rheumatoid synovial cells.

Yoshida K, Hashiramoto A, Okano T, Yamane T, Shibanuma N, Shiozawa S.

Scand J Rheumatol. 2013;42(4):276-80. doi: 10.3109/03009742.2013.765031. Epub 2013 Mar 16.

PMID:
23496259
9.

Shorter disease duration is important for tocilizumab to achieve Boolean remission.

Kawasaki Y, Hashimoto T, Okano T, Sakai Y, Yamane T, Shiozawa K, Shiozawa S, Hashiramoto A.

Mod Rheumatol. 2013 Nov;23(6):1192-7. doi: 10.1007/s10165-012-0822-7. Epub 2013 Feb 5.

PMID:
23380997
10.

Mixed connective tissue disease is distinct from systemic lupus erythematosus: study of major histocompatibility complex class I polypeptide-related sequence A and HLA gene polymorphisms.

Yoshida K, Inoue H, Komai K, Yamane T, Hashiramoto A, Shiozawa K, Shiozawa S.

Tissue Antigens. 2013 Jan;81(1):44-5. doi: 10.1111/tan.12027. No abstract available.

PMID:
23216288
11.

A study on the selection of DMARDs for the combination therapy with adalimumab.

Tanaka C, Shiozawa K, Hashiramoto A, Shiozawa S.

Kobe J Med Sci. 2012 Jun 27;58(2):E41-50.

12.

Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.

Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, Nagasawa H, Amano K, Saito K, Tanaka Y, Ito S, Sumida T, Ihata A, Ishigatsubo Y, Atsumi T, Koike T, Nakajima A, Tamura N, Fujii T, Dobashi H, Tohma S, Sugihara T, Ueki Y, Hashiramoto A, Kawakami A, Hagino N, Miyasaka N, Harigai M; REAL Study Group.

Ann Rheum Dis. 2012 Nov;71(11):1820-6. doi: 10.1136/annrheumdis-2011-200838. Epub 2012 Apr 13.

PMID:
22504558
13.

Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis.

Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, Amano K, Nakajima A, Atsumi T, Koike T, Ihata A, Ishigatsubo Y, Saito K, Tanaka Y, Ito S, Sumida T, Tohma S, Tamura N, Fujii T, Sugihara T, Kawakami A, Hagino N, Ueki Y, Hashiramoto A, Nagasaka K, Miyasaka N, Harigai M; Real Study Group.

Arthritis Care Res (Hoboken). 2012 Aug;64(8):1125-34. doi: 10.1002/acr.21666.

14.

Role of the MICA polymorphism in systemic lupus erythematosus.

Yoshida K, Komai K, Shiozawa K, Mashida A, Horiuchi T, Tanaka Y, Nose M, Hashiramoto A, Shiozawa S.

Arthritis Rheum. 2011 Oct;63(10):3058-66. doi: 10.1002/art.30501.

15.

Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.

Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M; REAL Study Group.

J Rheumatol. 2011 Jul;38(7):1258-64. doi: 10.3899/jrheum.101009. Epub 2011 Apr 15.

PMID:
21498482
16.

Pathogenesis of joint destruction in rheumatoid arthritis.

Shiozawa S, Tsumiyama K, Yoshida K, Hashiramoto A.

Arch Immunol Ther Exp (Warsz). 2011 Apr;59(2):89-95. doi: 10.1007/s00005-011-0116-3. Epub 2011 Feb 16. Review.

PMID:
21327737
17.

Heat shock protein 90 maintains the tumour-like character of rheumatoid synovial cells by stabilizing integrin-linked kinase, extracellular signal-regulated kinase and protein kinase B.

Hashiramoto A, Murata M, Kawazoe T, Yoshida K, Akiyama C, Shiozawa K, Shiozawa S.

Rheumatology (Oxford). 2011 May;50(5):852-61. doi: 10.1093/rheumatology/keq385. Epub 2010 Dec 21.

PMID:
21177334
18.

Interactions between the genes that regulate the body clock and those that worsen rheumatoid arthritis.

Shiozawa S, Hashiramoto A.

Expert Rev Clin Immunol. 2010 Mar;6(2):181-3. No abstract available.

PMID:
20402378
19.

Mammalian clock gene Cryptochrome regulates arthritis via proinflammatory cytokine TNF-alpha.

Hashiramoto A, Yamane T, Tsumiyama K, Yoshida K, Komai K, Yamada H, Yamazaki F, Doi M, Okamura H, Shiozawa S.

J Immunol. 2010 Feb 1;184(3):1560-5. doi: 10.4049/jimmunol.0903284. Epub 2009 Dec 30.

20.

Prospective study of methotrexate treatment for rheumatoid arthritis treated legitimately according to the government recommended 8 mg/week dose.

Hashiramoto A, Shiozawa K, Tanaka Y, Yamane T, Murata M, Tanaka C, Terashima Y, Koyama K, Nakagawa N, Abe S, Yoshihara R, Saegusa Y, Tsumiyama K, Komai K, Sakai Y, Shiozawa S.

Mod Rheumatol. 2009;19(6):637-42. doi: 10.1007/s10165-009-0205-x. Epub 2009 Jul 22.

PMID:
19626390
21.

Sjögren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment.

Komai K, Shiozawa K, Tanaka Y, Yoshihara R, Tanaka C, Sakai H, Yamane T, Murata M, Tsumiyama K, Hashiramoto A, Shiozawa S.

Mod Rheumatol. 2009;19(4):416-9. doi: 10.1007/s10165-009-0176-y. Epub 2009 May 19.

PMID:
19452244
22.

Low- versus high-baseline epinephrine output shapes opposite innate cytokine profiles: presence of Lewis- and Fischer-like neurohormonal immune phenotypes in humans?

Elenkov IJ, Kvetnansky R, Hashiramoto A, Bakalov VK, Link AA, Zachman K, Crane M, Jezova D, Rovensky J, Dimitrov MA, Gold PW, Bonini S, Fleisher T, Chrousos GP, Wilder RL.

J Immunol. 2008 Aug 1;181(3):1737-45.

23.

Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1.

Aikawa Y, Morimoto K, Yamamoto T, Chaki H, Hashiramoto A, Narita H, Hirono S, Shiozawa S.

Nat Biotechnol. 2008 Jul;26(7):817-23. doi: 10.1038/nbt1412. Epub 2008 Jun 29.

PMID:
18587386
24.

Easy and accurate diagnosis of rheumatoid arthritis using anti-cyclic citrullinated peptide 2 antibody, swollen joint count, and C-reactive protein/rheumatoid factor.

Yamane T, Hashiramoto A, Tanaka Y, Tsumiyama K, Miura Y, Shiozawa K, Chihara K, Shiozawa S.

J Rheumatol. 2008 Mar;35(3):414-20. Epub 2008 Jan 15.

PMID:
18203327
25.

Angiopoietin 1 directly induces destruction of the rheumatoid joint by cooperative, but independent, signaling via ERK/MAPK and phosphatidylinositol 3-kinase/Akt.

Hashiramoto A, Sakai C, Yoshida K, Tsumiyama K, Miura Y, Shiozawa K, Nose M, Komai K, Shiozawa S.

Arthritis Rheum. 2007 Jul;56(7):2170-9.

26.

Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis.

Hayashi S, Miura Y, Nishiyama T, Mitani M, Tateishi K, Sakai Y, Hashiramoto A, Kurosaka M, Shiozawa S, Doita M.

Arthritis Rheum. 2007 Apr;56(4):1067-75.

27.

Fasciitis: what is the significance of various forms?

Shiozawa S, Miura Y, Hashiramoto A, Murata M, Takabayashi C, Shiozawa K, Kuroki Y.

J Clin Rheumatol. 2003 Feb;9(1):1-3. No abstract available.

PMID:
17041414
28.

Serum levels and pharmacodynamics of methotrexate and its metabolite 7-hydroxy methotrexate in Japanese patients with rheumatoid arthritis treated with 2-mg capsule of methotrexate three times per week.

Shiozawa K, Tanaka Y, Yoshihara R, Imura S, Murata M, Yamane T, Miura Y, Hashiramoto A, Shiozawa S.

Mod Rheumatol. 2005;15(6):405-9.

PMID:
17029103
29.

Hypermethylated promoter region of DR3, the death receptor 3 gene, in rheumatoid arthritis synovial cells.

Takami N, Osawa K, Miura Y, Komai K, Taniguchi M, Shiraishi M, Sato K, Iguchi T, Shiozawa K, Hashiramoto A, Shiozawa S.

Arthritis Rheum. 2006 Mar;54(3):779-87.

30.

Ganglioside GM3 promotes cell migration by regulating MAPK and c-Fos/AP-1.

Hashiramoto A, Mizukami H, Yamashita T.

Oncogene. 2006 Jun 29;25(28):3948-55. Epub 2006 Feb 20.

PMID:
16491123
31.

[Molecular genetics of rheumatic diseases].

Hashiramoto A, Komai K, Shiozawa S.

Nihon Rinsho. 2005 Dec;63 Suppl 12:228-31. Review. Japanese. No abstract available.

PMID:
16416799
32.

Anchorage on fibronectin via VLA-5 (alpha5beta1 integrin) protects rheumatoid synovial cells from Fas-induced apoptosis.

Kitagawa A, Miura Y, Saura R, Mitani M, Ishikawa H, Hashiramoto A, Yoshiya S, Shiozawa S, Kurosaka M.

Ann Rheum Dis. 2006 Jun;65(6):721-7. Epub 2005 Oct 25.

33.

Estrogen specifically stimulates expression and production of osteoprotegerin from rheumatoid synovial fibroblasts.

Mitani M, Miura Y, Saura R, Kitagawa A, Fukuyama T, Hashiramoto A, Shiozawa S, Kurosaka M, Yoshiya S.

Int J Mol Med. 2005 May;15(5):827-32.

PMID:
15806305
34.

[Susceptibility genes in rheumatoid arthritis: mutation in DR3 gene].

Shiozawa S, Hashiramoto A, Osawa K, Takami N, Miura Y, Kurosaka M, Yoshiya S, Koyama K, Terashima Y, Abe S, Nakagawa N, Saegusa Y, Tanaka Y, Shiozawa K, Iguchi T.

Nihon Rinsho. 2005 Jan;63 Suppl 1:122-6. Review. Japanese. No abstract available.

PMID:
15799330
35.

Heat shock protein 90 is required for increased DNA binding activity of activator protein-1, a heterodimer of Fos/JunD, in rheumatoid synovial cells under inflammatory stimuli.

Murata M, Miura Y, Hashiramoto A, Kitamura H, Kawasaki H, Shiozawa K, Yoshiya S, Baba H, Chihara K, Shiozawa S.

Int J Mol Med. 2005 Apr;15(4):649-53.

PMID:
15754027
36.

A case of central nervous system lupus in succession to lupus peritonitis: a difficulty in the differential diagnosis between lupus psychosis and steroid-induced psychosis.

Murata M, Hashiramoto A, Yamaguchi T, Takabayashi C, Yamane T, Miura Y, Baba H, Chihara K, Shiozawa S.

Mod Rheumatol. 2004 Sep;14(4):323-6. doi: 10.3109/s10165-004-0318-1.

PMID:
24387654
37.

Death receptor 3 (DR3) gene duplication in a chromosome region 1p36.3: gene duplication is more prevalent in rheumatoid arthritis.

Osawa K, Takami N, Shiozawa K, Hashiramoto A, Shiozawa S.

Genes Immun. 2004 Sep;5(6):439-43.

PMID:
15241467
38.

Human wee1 kinase is directly transactivated by and increased in association with c-Fos/AP-1: rheumatoid synovial cells overexpressing these genes go into aberrant mitosis.

Kawasaki H, Komai K, Nakamura M, Yamamoto E, Ouyang Z, Nakashima T, Morisawa T, Hashiramoto A, Shiozawa K, Ishikawa H, Kurosaka M, Shiozawa S.

Oncogene. 2003 Oct 9;22(44):6839-44.

PMID:
14534529
39.

p21waf1/cip1 is down-regulated in conjunction with up-regulation of c-Fos in the lymphocytes of rheumatoid arthritis patients.

Hikasa M, Yamamoto E, Kawasaki H, Komai K, Shiozawa K, Hashiramoto A, Miura Y, Shiozawa S.

Biochem Biophys Res Commun. 2003 Apr 25;304(1):143-7.

PMID:
12705898
40.

Enhanced insulin sensitivity in mice lacking ganglioside GM3.

Yamashita T, Hashiramoto A, Haluzik M, Mizukami H, Beck S, Norton A, Kono M, Tsuji S, Daniotti JL, Werth N, Sandhoff R, Sandhoff K, Proia RL.

Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3445-9. Epub 2003 Mar 10.

41.
42.

Modulation of multiple experimental arthritis models by collagen-induced arthritis quantitative trait loci isolated in congenic rat lines: different effects of non-major histocompatibility complex quantitative trait loci in males and females.

Remmers EF, Joe B, Griffiths MM, Dobbins DE, Dracheva SV, Hashiramoto A, Furuya T, Salstrom JL, Wang J, Gulko PS, Cannon GW, Wilder RL.

Arthritis Rheum. 2002 Aug;46(8):2225-34.

43.

ACTH expression in synovium of patients with rheumatoid arthritis and Lewis rats with adjuvant arthritis.

Miyazaki S, Yoshikawa T, Hashiramoto A, Yamada R, Tsubouchi Y, Kohno M, Kawahito Y, Kondo M, Sano H.

Mod Rheumatol. 2002 Sep;12(3):206-12. doi: 10.3109/s101650200036.

PMID:
24387059
44.

Application of interval haplotype analysis facilitates efficient mapping of the mutation causing osteopetrosis in tl rats.

Remmers EF, Hansen CT, Hashiramoto A, Wilder RL, Dobbins DE.

Mamm Genome. 2002 Jun;13(6):299-301. No abstract available.

PMID:
12115032
45.

Mutation of macrophage colony stimulating factor (Csf1) causes osteopetrosis in the tl rat.

Dobbins DE, Sood R, Hashiramoto A, Hansen CT, Wilder RL, Remmers EF.

Biochem Biophys Res Commun. 2002 Jun 28;294(5):1114-20.

PMID:
12074592
46.

Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells.

Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, Inoue K, Kusaka Y, Kondo M, Sano H.

J Rheumatol. 2001 Dec;28(12):2591-6.

PMID:
11764202
47.

Urocortin expression in synovium of patients with rheumatoid arthritis and osteoarthritis: relation to inflammatory activity.

Kohno M, Kawahito Y, Tsubouchi Y, Hashiramoto A, Yamada R, Inoue KI, Kusaka Y, Kubo T, Elenkov IJ, Chrousos GP, Kondo M, Sano H.

J Clin Endocrinol Metab. 2001 Sep;86(9):4344-52.

PMID:
11549672
48.

Polymorphisms of the tumor necrosis factor receptor type 1 locus among autoimmune susceptible and resistant inbred rat strains.

Furuya T, Salstrom JL, Joe B, Hashiramoto A, Dobbins DE, Wilder RL, Remmers EF.

Immunogenetics. 2001 Jul;53(5):427-9. No abstract available.

PMID:
11486281
49.

Polymorphisms of the tumor necrosis factor alpha locus among autoimmune disease susceptible and resistant inbred rat strains.

Furuya T, Joe B, Salstrom JL, Hashiramoto A, Dobbins DE, Wilder RL, Remmers EF.

Genes Immun. 2001 Jun;2(4):229-32.

50.

15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats.

Kawahito Y, Kondo M, Tsubouchi Y, Hashiramoto A, Bishop-Bailey D, Inoue K, Kohno M, Yamada R, Hla T, Sano H.

J Clin Invest. 2000 Jul;106(2):189-97.

Supplemental Content

Loading ...
Support Center